SEOUL, South Korea — FirstBioTherapeutics, a South Korean biotech startup, announced on July 30 that it has been selected for NVIDIA’s Inception program, a global initiative designed to support startups in artificial intelligence, data science, and high-performance computing.
The NVIDIA Inception program provides selected companies with access to software development tools, GPU technology, technical seminars, and connections to global venture capital networks. This support is aimed at accelerating innovation in cutting-edge fields.
FirstBioTherapeutics is leveraging AI to enhance the efficiency of small-molecule drug discovery, increasing the likelihood of identifying promising drug candidates. Through its participation in the Inception program, the company plans to utilize NVIDIA’s software development kits and the BioNeMo platform to improve the precision of protein structure prediction and drug candidate design.
The company will also collaborate with NVIDIA’s development team to receive technical feedback, refine its proprietary AI models, and participate in global conferences and technical seminars to expand partnership opportunities.
“Joining NVIDIA Inception will strengthen our AI-driven drug development capabilities, enabling us to enhance research efficiency and predictive accuracy,” said Jae-eun Kim, CEO of FirstBioTherapeutics.
In addition to this milestone, FirstBioTherapeutics was named a preliminary unicorn company by South Korea’s Ministry of SMEs and Startups in 2024. The company is also actively collaborating with Naver Cloud and Dassault Systèmes on AI-based drug development projects.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr